Trial Profile
Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Mar 2020 Results published in the Targeted Oncology.
- 10 Sep 2019 Results (data cut off Sep 28 2018) assessing overall survival presented at the 20th World Conference on Lung Cancer
- 15 Sep 2017 Results assessing efficacy of combination of pemetrexed plus carboplatin and gefitinib in patients with non small cell lung cancer, were published in the International Journal of Cancer.